Tallantyre, Emma C. ![]() ![]() ![]() |
Preview |
PDF
- Accepted Post-Print Version
Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (329kB) | Preview |
Abstract
Anti-CD20 monoclonal antibodies are commonly used to manage neuroinflammatory diseases. The rate of B-cell re-emergence after dosing of ocrelizumab or rituximab varies considerably between individuals, but most people remain completely B-cell depleted at 6 months. Tailoring the dosing according to B-cell re-emergence may improve the safety profile of anti-CD20s but poses logistical challenges such as the need for regular attendances for whole-blood sampling. Here we combined a quantitative dried blood spot sampling technique with a DNA methylation test, to provide a reliable means of remotely monitoring B-cell counts, with 100% sensitivity and specificity for reaching >10 × 106 cells/L.
Item Type: | Article |
---|---|
Date Type: | Published Online |
Status: | In Press |
Schools: | Schools > Medicine |
Publisher: | Sage |
ISSN: | 1352-4585 |
Funders: | N/A |
Date of First Compliant Deposit: | 3 April 2025 |
Date of Acceptance: | 13 March 2025 |
Last Modified: | 03 Apr 2025 15:45 |
URI: | https://orca.cardiff.ac.uk/id/eprint/177323 |
Actions (repository staff only)
![]() |
Edit Item |